GH Research PLC

GHRS

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Avoro Capital Advisors RTW Investments RA Capital Management

Position Trend

Feb 17, 2026

$285.0M

3 funds

Mar 16, 2026

$22.9M

1 fund

-92% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management12.4%Aug 14, 2025

SC 13G/ARA Capital Management11.2%May 15, 2025

SC 13G/A

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 1,800,000Value: $22.9M

# Signal Note: Avoro Capital Initiates $22.9M Position in GH Research **Avoro's $22.9M entry into GHRS suggests confidence in GH Research's psilocybin-assisted therapy program for treatment-resistant depression (TRD).** The biotech specialist's initiation likely reflects positive interim data expectations ahead of Phase 2b readout (anticipated late 2024/early 2025) for GH001, which would be the first psilocybin therapy to enter Phase 2b in TRD if approved. **Key catalyst risk: regulatory pathway clarity on psilocybin scheduling and FDA feedback on the trial design could significantly influence commercial viability.**

RTW InvestmentsNEW

More GHRS Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TSHA3 funds FDMT3 funds GPCR3 funds SEPN3 funds IRON3 funds KYMR3 funds PCSC2 funds RNA

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RTW Investments Initiates $75.4M Position in GHRS RTW's new 5.9M share position suggests conviction in GH Research's clinical pipeline, likely driven by upcoming Phase 2b data for GH001 (psilocybin) in treatment-resistant depression (TRD), expected 1H 2025. The $75.4M commitment indicates confidence in the asset's competitive positioning within the psychedelic-assisted therapy space, where regulatory pathways remain de-risked following FDA breakthrough therapy designation. Watch for upcoming trial readouts and any partnership developments that could validate valuation.